Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney Breen from Bernstein maintained a Buy rating on the stock and has a $1,100.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Courtney Breen’s rating is based on the promising developments in Eli Lilly & Co’s clinical programs and their potential impact on the company’s growth. The upcoming American Diabetes Association meeting will feature key data releases from Lilly, including the detailed presentation of the ACHIEVE-1 study for orforglipron, which is part of their late-stage clinical program. Additionally, Lilly is expected to present data on bimagrumab, a muscle-wasting agent, and the first clinical data for their long-acting amylin, Eloralintide, which could enhance weight loss treatments.
These developments highlight Lilly’s innovative pipeline and potential for future growth, making it a compelling investment opportunity. The anticipation of these data releases and their implications for Lilly’s product offerings contribute to the Buy rating, as they could significantly enhance the company’s market position and drive long-term value for shareholders.
Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Pfizer. According to TipRanks, Breen has an average return of 3.3% and a 57.89% success rate on recommended stocks.
In another report released yesterday, UBS also reiterated a Buy rating on the stock with a $1,050.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue